TREM-1

TREM-1 Molekülinformation

Englischer Name	Triggering receptor expressed on myeloid cells 1	Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	6	Target-Alias	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

Englischer Name	Triggering receptor expressed on myeloid cells 1
Target-Alias	Triggering Receptor Expressed On Myeloid Cells 1，CD354 Antigen，Triggering Receptor Expressed on Myeloid Cells-1，TREM-1，TREM1，CD354，Triggering receptor expressed on monocytes 1
Anzahl der inverkehr gebrachten Arzneimittel	0
Anzahl der klinischen Arzneimittel	6
Höchste Forschungs- und Entwicklungsphase	Phase 2 Clinical

TREM-1 Produktliste

Attribut
Protein (1)
Produktbibliothek
Online (1)
Spezies
Human (1)
Etikett
Fc Tag (1)
Marker
Unconjugated (1)

Produktnummer	Spezies	Expressionssystem	Produktbeschreibung	Proteinstruktur	Reinheit	Eigenschaften	Vorbestellen/Bestellen
TR1-H5251	Human	HEK293	Human TREM-1 / CD354 Protein, Fc Tag, low endotoxin				In den Warenkorb legen

Gesamtmenge1

Produktanfrage

TREM-1 Molekülhintergrund

Triggering receptor expressed on myeloid cells 1 (TREM1) is also known as CD antigen CD354, and is a type I transmembrane protein with a single Ig-like domain. TREM1 is highly expressed in adult liver, lung and spleen than in corresponding fetal tissue. TREM-1 / CD354 stimulates neutrophil and monocyte-mediated inflammatory responses, and also triggers release of pro-inflammatory chemokines and cytokines, as well as increased surface expression of cell activation markers. Amplifier of inflammatory responses that are triggered by bacterial and fungal infections and is a crucial mediator of septic shock. TREM1 can interacts with TYROBP / DAP12.

TREM-1 Molekülalias

TREM1,CD354

Klinische Arzneimittelinformation

Englischer Name	Forschungscode	Forschungsphase	Firma	Indikationen	Klinische Studie
Nangibotide	LR-12	Phase 2 Clinical	Inotrem	Coronavirus Disease 2019 (COVID-19); Shock, Septic	Details
ABBV-8736	ABBV-8736	Phase 2 Clinical	Abbvie Inc	Crohn Disease; Inflammatory Bowel Diseases	Details
TREM-1 antibody (Boehringer Ingelheim)		Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Autoimmune Diseases	Details
CEL383	CEL-383	Phase 1 Clinical	Celsius Therapeutics Inc	Inflammatory Bowel Diseases	Details
TREM 1 antibody(Boehringer Ingelheim International Gmbh)	TREM 1 antibody(Boehringer Ingelheim International Gmbh)	Phase 1 Clinical	Boehringer Ingelheim International Gmbh	Immune System Diseases	Details
PY-159	PY-159	Phase 1 Clinical	Centre for the Commercialization of Antibodies and Biologics	Neoplasms; Solid tumours	Details